Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection approved for registration in the United States.

Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that its drug Enoxaparin Sodium Injection has obtained approval for its Abbreviated New Drug Application (ANDA) in the United States from the Food and Drug Administration (FDA). The announcement states that Enoxaparin Sodium Injection is used for the prevention of venous thromboembolic diseases (prevention of intravenous blood clot formation), especially related to orthopedic or general surgery; treatment of established deep vein thrombosis, with or without pulmonary embolism, with mild clinical symptoms, excluding pulmonary embolism requiring surgical intervention or thrombolytic therapy; used in combination with aspirin for the treatment of unstable angina and non-Q wave myocardial infarction; used in extracorporeal circulation in hemodialysis to prevent clot formation.